Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

19.36 -0.29 (-1.48%)
Streaming Delayed Price Updated: 11:49 AM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Here are the top movers in Tuesday's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Tuesday's session: top gainers and losers
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Earnings Scheduled For August 4, 2025
 
Via Benzinga
Sterling Infrastructure Posts Better-Than-Expected Earnings, Joins Lemonade, DigitalOcean Holdings, Lattice Semiconductor And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Traders are paying attention to the gapping stocks in Tuesday's session.
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
These stocks are moving in today's pre-market session
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Castle (CSTL) Q2 Revenue Tops Estimates
Via The Motley Fool
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Castle Biosciences Inc (NASDAQ:CSTL) Surges After Posting Strong Q2 2025 Earnings Beat
Castle Biosciences (CSTL) Q2 2025 earnings beat estimates with $86.19M revenue & $0.15 EPS, driving a 6% after-hours surge. Strong test volume growth fuels optimism. 
Via Chartmill
Topics Earnings
Castle Biosciences Reports Second Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
Examining the Future: Castle Biosciences's Earnings Outlook
 
Via Benzinga
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful... 
From Castle Biosciences, Inc.
Via GlobeNewswire
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards 
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic Dermatitis 
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
From Castle Biosciences, Inc.
Via GlobeNewswire
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients 
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Celebrates Skin Cancer Awareness Month
From Castle Biosciences, Inc.
Via GlobeNewswire
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Castle Biosciences Reports First Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Acquire Previse
From Castle Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.